AU2002228648A1 - Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists - Google Patents

Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists

Info

Publication number
AU2002228648A1
AU2002228648A1 AU2002228648A AU2864802A AU2002228648A1 AU 2002228648 A1 AU2002228648 A1 AU 2002228648A1 AU 2002228648 A AU2002228648 A AU 2002228648A AU 2864802 A AU2864802 A AU 2864802A AU 2002228648 A1 AU2002228648 A1 AU 2002228648A1
Authority
AU
Australia
Prior art keywords
antagonists
combined therapy
estramustine phosphate
against tumors
therapy against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002228648A
Inventor
Jeffrey H. Buchalter
Ivan D. Horak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of AU2002228648A1 publication Critical patent/AU2002228648A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
AU2002228648A 2000-11-16 2001-11-06 Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists Abandoned AU2002228648A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71460600A 2000-11-16 2000-11-16
US09/714,606 2000-11-16
PCT/US2001/044161 WO2002039996A2 (en) 2000-11-16 2001-11-06 Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists

Publications (1)

Publication Number Publication Date
AU2002228648A1 true AU2002228648A1 (en) 2002-05-27

Family

ID=24870732

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002228648A Abandoned AU2002228648A1 (en) 2000-11-16 2001-11-06 Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists

Country Status (2)

Country Link
AU (1) AU2002228648A1 (en)
WO (1) WO2002039996A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
AU2003280688A1 (en) * 2003-10-31 2005-05-19 Kurume University Combination therapy of peptide vaccination and estramustine treatment
JP4905624B2 (en) * 2003-10-31 2012-03-28 学校法人 久留米大学 Combination therapy of peptide vaccine administration and estramustine treatment
MX2007015949A (en) 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof.
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2794734C (en) 2010-03-30 2017-12-12 Phosphagenics Limited Transdermal delivery patch
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd Amino-quinolines as kinase inhibitors
BR112019012946A2 (en) 2016-12-21 2019-11-26 Avecho Biotechnology Ltd process

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues

Also Published As

Publication number Publication date
WO2002039996A2 (en) 2002-05-23
WO2002039996A3 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
ZA200108291B (en) Diaminothiazoles and their use for inhibiting protein kinases.
HUP0600780A2 (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
AU2001253126A1 (en) (+) naloxone and epinephrine combination therapy
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001266910A1 (en) Secure medical test and result delivery system
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
AU715620C (en) Therapeutic methods and uses
AU1164601A (en) Therapeutic use and formulation
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
HK1040077A1 (en) Substituted-3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases
HK1043059A1 (en) Tumor necrosis factor antagonists and their use inendometriosis.
IL211081A0 (en) Methods and devices for providing prolonged drug therapy
AU2001261788A1 (en) Management and delivery of online webcasts
AU2002228648A1 (en) Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists
AU2292301A (en) Human kinases
AU2001243515A1 (en) Combination drug therapy
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2002234165A1 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
AU2962200A (en) Use of agonists or antagonists of mip-3a in therapy
GB2363658B (en) Gaming systems and methods
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU6111800A (en) 26 human prostate and prostate cancer associated proteins
AU2001279090A1 (en) Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases
AU4452900A (en) Compositions and methods for the therapy and diagnosis of prostate cancer